Melissa officinalis

Within the SIRIAM Platform, Melissa officinalis is classified as a Regional Signature Component rather than a universal platform ingredient.

Unlike the Structural & Dermal Support Core, Release Core and Integration Core ingredients, which are shared across multiple formulations, Regional Signature Components provide the anatomical individuality of each SIRIAM preparation. Their selection is determined by the physiological objectives of a specific neurodermal region rather than by the common platform architecture.

Within this framework, Melissa officinalis is incorporated into formulations where modulation of cutaneous neurophysiology, local autonomic balance and epidermal homeostasis are considered relevant to the intended regional design. Its inclusion therefore reflects an anatomically targeted pharmaceutical strategy rather than a universally applied botanical component.

Melissa officinalis (Lemon Balm) is a perennial medicinal plant belonging to the Lamiaceae family and has been widely used in European herbal medicine for centuries.

Its principal phytochemical constituents include:

Rosmarinic acid

caffeic acid derivatives

flavonoids

triterpenes

essential oils (including citronellal, citral and geraniol)

Experimental studies demonstrate multiple biological mechanisms, including:

antioxidant activity;

modulation of inflammatory signalling pathways;

reduction of oxidative stress;

antimicrobial activity;

influence on GABAergic neurotransmission;

modulation of neuronal excitability in experimental models.

Human clinical research has primarily evaluated oral Melissa preparations, particularly in relation to mild anxiety, sleep quality and stress-related symptoms. Several controlled trials suggest modest improvements in subjective wellbeing and stress regulation, although study heterogeneity remains substantial.

Topical research is considerably more limited. The strongest evidence concerns herpes simplex labialis (cold sores), where standardized topical Melissa officinalis preparations have demonstrated reductions in symptom severity and healing time in several clinical studies.

Outside herpes-related applications, evidence for topical neurophysiological effects remains limited and largely experimental.

Current scientific evidence evaluates Melissa officinalis primarily as an isolated botanical extract or within conventional pharmaceutical formulations.

No published studies currently investigate Melissa officinalis within a region-specific neurodermal formulation architecture comparable to the SIRIAM Platform. Consequently, its incorporation reflects biological plausibility together with the architectural design philosophy of the platform rather than established evidence for this specific pharmaceutical application.

Within the SIRIAM Platform, Melissa officinalis functions as a Regional Signature Component.

Unlike platform-wide ingredients, it is incorporated selectively according to the physiological objectives of specific regional formulations.

Its concentration, extract standardisation and anatomical application remain subject to ongoing pharmaceutical optimisation as the regional architecture of the platform continues to evolve.